Sol-Gel Technologies Total Change in Assets/Liabilities 2016-2024 | SLGL
Sol-Gel Technologies total change in assets/liabilities from 2016 to 2024. Total change in assets/liabilities can be defined as the sum of all line items in the Asset/Liability section of the Cash Flows Statement
Sol-Gel Technologies Annual Total Change in Assets/Liabilities
(Millions of US $) |
| 2023 |
$8 |
| 2022 |
$4 |
| 2021 |
$-12 |
| 2020 |
$2 |
| 2019 |
$-1 |
| 2018 |
$3 |
| 2017 |
$-3 |
| 2016 |
$1 |
| 2015 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.016B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
